Company profilePharmaceutical#90 of 1,318 in Pakistan1 DRAP alert

ENGLISH PHARMACEUTICALS INDUSTRIES

Pharmaceutical company · 180 brands · 252 molecules

Ranked #9 of 213 companies in Other Beta-Lactam, Cephalosporins & Penems

180 registered products 64 pharmaceutical brands 252 distinct molecules 1 DRAP alert

Company overview

180
registered products
64
pharmaceutical brands
252
distinct molecules
12
therapeutic classes
1
DRAP alerts

ENGLISH PHARMACEUTICALS INDUSTRIES is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 180 product registrations across 252 distinct molecules. It is the 90th largest registrant in Pakistan by product count, and ranks 9th of 213 in Other Beta-Lactam, Cephalosporins & Penems. Its portfolio is concentrated in Other Beta-Lactam, Cephalosporins & Penems and Antiinflammatory And Antirheumatic Products. DRAP has issued 1 alert involving its products.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by ENGLISH

98 products matched in our catalogue · showing 80 — each with its observed price and DRAP approved ceiling.

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

90
ceilings with an approval date
2
not revised in 2+ years
2024
oldest approval year
20242
20251
202687
Longest without revision

Top molecules by brand count

Pyridoxine8 brands
Valsartan7 brands
Thiamine7 brands
Riboflavin6 brands
Amlodipine6 brands
Ampicillin5 brands
Diclofenac5 brands
Nicotinamide4 brands
Iron Salts4 brands
Folic Acid4 brands

Therapeutic classes

Other Beta-Lactam, Cephalosporins & Penems · 14Antiinflammatory And Antirheumatic Products · 12Angiotensin-Ii Antagonists, Combinations · 9Antihistamines For Systemic Use · 8Quinolone Antibacterials · 7Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord) · 7Multivitamin, Combinations · 6Macrolides, Lincosamides And Streptogramins · 5Antiepileptics · 4Beta-Lactam Antibacterials, Penicillins · 4Antianemic, Iron Preparations · 4Antiemetics & Antinauseants · 4

Conditions treated

General Infections · 2Bleeding Disorder · 1URINARY TRACT INFECTION · 1Ulcer/Reflux/Flatulence/Acidity · 1Bladder & Prostate Disorder · 1Anaemia · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official60 products · Rs 18.27 – Rs 263,708.44
DVAGO2 products · Rs 1,250.07 – Rs 2,793
Servaid8 products · Rs 101.45 – Rs 1,346.55
Median across source: Rs 482

Regulatory record

1 alert in the DRAP feed we track.

Recall Alert: Drug Product; Diamicron 80mg Tablets (Batch#1740) by M/s. Servier Research &
2022-11-29

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

Wilshire Laboratories (Private) Limited holds 105 molecules not in this portfolio
AcyclovirAcyclovir SodiumAlfacalcidolAmlodipineAmoxycillinAnastrozole
NEUTRO PHARMA (PVT) LTD. holds 100 molecules not in this portfolio
AcetylcysteineAcyclovirAlbendazoleAnastrazoleAnastrozoleAntimony
BIO LABS (PVT) LTD. holds 110 molecules not in this portfolio
AmlodipineAprepitantAremetherArtemetherArtesunateAzathioprine

Get the full profile for ENGLISH

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.